The spliceosome as target for anticancer treatment

British Journal of Cancer

Volumn 100, Issue 2, 2009, Pages 228-232

  Van Alphen, R J ^a   Wiemer, E A C ^a   Burger, H ^a   Eskens, F A L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alternative splicing; E 7107; Planiedolide; Spliceosome; Spliceostatin A

Indexed keywords

ANTINEOPLASTIC AGENT; E 7107; FR 901464; MESSENGER RNA; PLADIENOLIDE; PLADIENOLIDE B; PLADIENOLIDE D; SPLICEOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; RNA SPLICING; RNA TRANSCRIPTION; SPLICEOSOME; TUMOR; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; INTRONS; NEOPLASMS; RIBONUCLEOPROTEINS; SPLICEOSOMES;

EID: 58749105294     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604801     Document Type: Review

References (31)

1. Allemand E, Hastings ML, Murray MV, Myers MP, Krainer AR (2007) Alternative splicing regulation by interaction of phosphatase PP2Cγ with nucleic acid-binding protein YB-1. Nature Struct Mol Biol 14: 630-638
2. Barbier J, Dutertre M, Bittencourt D, Sanchez G, Gratadou L, de la Grange P, Auboeuf D (2007) Regulation of H-ras splice variant expression by cross talk between the p53 and nonsense-mediated mRNA decay pathways. Mol Cell Biology 27: 7315-7533
3. Ben-Dov C, Hartmann B, Lundgren J, Valcárcel J (2008) Genome-wide analysis of alternative pre-mRNA splicing. Biol Chem 18: 1229-1233
4. Blencowe BJ (2006) Alternative splicing: new insights form global analyses. Cell 126: 37-47
5. Disher K, Skandalis A (2007) Evidence of the modulation of mRNA splicing fidelity in humans by oxidative stress and p53. Genome 50: 946-953
6. Heider KH, Kuthan H, Stehle G, Munzert G (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53: 567-579
7. House AE, Lynch K (2008) Regulation of alternative splicing: more than just the ABCs. J Biol Chemistry 283: 1217-1221
8. Iwata M, Ozawa I, Uenaka T, Shimizu H, Niijima J, Kanada R, Fukuda Y, Nagai M, Kotake Y, Yoshida M, Tsuchida T, Mizui Y, Yoshimatsu K, Asada M. (2004) E7107, a new urethane derivative of pladienolide D, displays curative effect against several human tumour xenografts. Proc Amer Assoc Cancer Res 45: 691 (abstract 2989)
9. Jurica MS, Moore MJ (2003) Pre-mRNA splicing: awash in a sea of proteins. Mol Cell 28: 336-345
10. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M (2007) Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nature Chem Biol 3: 576-583
11. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y (2007) Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nature Chem Biol 3: 570-575
12. Laverman P, Roosenburg S, Gotthardt M, Park J, Oyen WJG, de Jong M, Hellmich MR, Rutjes FPJT, van Delft FL, Boerman OC (2008) Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin. Eur J Med Mol Imaging 35: 386-392
13. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M (2004) Pladienolides, new substances from culture of Streptococcus platensis Mer-11107, III. In vitro and in vivo antitumor activities. J Antibiotics (Tokyo) 57: 188-196
14. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Sumi K, Yomoda J, Murray MV, Kimura H, Furuichi K, Shibuya H, Krainer AR, Suzuki M, Hagiwara M (2004) Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 23: 24246-24254
15. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S, Shimomura K (1996) New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot 12: 1204-1211
16. Orban TI, Olah E (2003) Emerging roles of BRCA1 alternative splicing. Mol Pathol 56: 191-197
17. Pilch B, Allemand E, Facompré M, Bailly C, Riou JF, Soret J, Tazi J (2001) Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 18: 6876-6884
18. Rino J, Carvalho T, Braga J, Desterro JMP, Lührmann R, Carmo-Fonseca M (2007) A stochastic view of spliceosome assembly and recycling in the nucleus. PLoS Comput Biol 3: 2019-2031
19. Singh RN (2007) Evolving concepts on human SMN pre-mRNA splicing. RNA Biology 4: 7-10
20. Skotheim RI, Nees M (2007) Alternative splicing in cancer: noise, functional or systematic? Int J Biochem Cell Biology 30: 292-302
21. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W, Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J (2005) Selective modification of alternative splicing bt indolederivatives that target the serine-arginine-rich protein splicing factors. Proc Natl Acad Sci USA 102: 8764-8769
22. Staley JP, Guthrie C (1998) Mechanical devices of the spliceosome: motors, clocks springs and things. Cell 92: 315-326
23. Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C (2005a) Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diosporin derivatives. Mol Pharmacol 67: 1186-1194
24. Tazi J, Durand S, Jeanteur P (2005b) The spliceosome: a novel multi-faceted target for therapy. Trends Biochem Sci 30: 469-575
25. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GL, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686
26. Vela E, Hilari JM, Roca X, Muñoz-Mármol AM, Ariza A, Isamat M (2007) Multisite and bidirectional exonic splicing enhancer in CD44 alternative exon v3. RNA 13: 1-12
27. Wang Z, Burge CB (2008) Splicing regulation: from a parts list or regulatory elements to an integrated splicing code. RNA 14: 802-813
28. Will CL, Lührmann R (2001) Spliceosomal UsnRNP biogenesis, structure and function. Currt Opin in Struct Biol 13: 290-301
29. Xiang C, Sarid R, Cazacu S, Finnis S, Lee H-K, Ziv-Av A, Mikkelsen T, Brodie C (2007) Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells. Biochem and Biophys Res Commun 362: 612-618
30. Yu C-P, Yu J-C, Sun C-A, Tzao C, Ho J-Y, Yen AM-F (2007) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107: 95-102
31. Zhou Z, Licklider LJ, Gygi SP, Reed R (2002) Comprehensive proteomic analysis of the human spliceosome. Nature 419: 182-185